Pyruvate carboxylase can be used in the research of prediabetes type 2 and NSCLC [1] [2]
Anti-inflammatory properties
Disclosures: Brandon Lehrich: Nothing to Disclose, Junyan Tao: Nothing to Disclose, Evan Delgado: Nothing to Disclose, Catherine Cao: Nothing to Disclose, Tyler Yasaka: Nothing to Disclose, Yuqing Liu: Nothing to Disclose, Minakshi Poddar: Nothing to Disclose, Sucha Singh: Nothing to Disclose, Xiangnan Guan: Nothing to Disclose, Hartmut Koeppen: Nothing to Disclose, Silvia Liu: Nothing to Disclose, Yulei Wang: Nothing to Disclose, Satdarshan (Paul) Monga: Alnylam: Grant/Research Support, Alnylam: Consultant, Surrozen: Independent Contractor, Fog Pharmaceuticals: Grant/Research Support, Mermaid Bio: Advisor, Vicero: Advisor, AntlerA: Advisor, Genentech: Speaking and Teaching, Surrozen: Consultant 1914 EXOSOMAL MIRNA AS A VALUABLE INDICATOR FOR PREDICTING THE RESPONSE OF ATEZOLIZUMAB AND BEVACIZUMAB COMBINATION THERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA Eunho Choi 1 Young-Sun Lee 1 Jeong-An Gim 2 Wonhyo Seo 3 Ha Seok Lee 1 Youngwoo Lee 1 Yang Jae Yoo 1 Seong Hee Kang 1 Sun Young Yim 1 Young Kul Jung 1 Ji Hoon Kim 1 Yeon Seok Seo 1 Hyung Joon Yim 1 Jong Eun Yeon 1 Kwan Soo Byun 1 , 1 Korea University College of Medicine, 2 Soonchunhyang University, 3 Ewha Womans University Background: Atezolizumab and bevacizumab combination therapy is the frontline treatment for advanced hepatocellular carcinoma, but identifying a reliable biomarker for predicting treatment response remains elusive
Overall I feel better
